Study analysis · Scientific Reports · 2017
Your prostate cancer treatment might be silently weakening your bones—but not as much as you think.
After a year of hormone therapy for prostate cancer, bones get a little weaker, but the risk of breaking a bone stays very low—no matter which treatment you get.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study watched two groups of men with prostate cancer over a year to see how their bones changed after different treatments. It found that both treatments made bones weaker, but it couldn't say for sure if one was worse than the other because the doctors chose which treatment each man got — not by chance.
What’s the bottom line?
Men with prostate cancer get a treatment that lowers testosterone to fight cancer, but this can make bones weaker. This study checked if two types of this treatment hurt bones differently.
How strong is this study?
The study tried hard by measuring bones carefully and tracking many things like age and exercise, but it wasn't fair because the doctors picked who got which treatment, and one group had way more men than the other. That makes it harder to trust the results — it's like comparing a big class to a tiny one and saying they're the same, even though they started out different.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
49 / 100
- Randomizationnot randomized
- Blindingblinding unclear
- Control group+15/15
- Sample size (n=253)+14.4/20
- Follow-up+10/10
100 / 100
77 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 556 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. This is an observational cohort study without randomization or blinding, so it cannot rule out confounding factors (e.g., baseline differences in prostate volume, nodal stage, exercise levels, and treatment selection bias). The assignment to treatment groups was based on physician discretion, not random assignment, making it impossible to conclude that one treatment caused different bone loss outcomes.
No Conflicts
No conflicts of interest identified
No conflicts of interest or funding disclosures were reported in the study text. The study appears to be independently conducted without industry involvement.
The study was conducted across 10 university hospitals in South Korea with institutional review board approvals and informed consent. No industry sponsors, author affiliations with pharmaceutical companies, or funding disclosures were identified. The statistical analysis was performed by a PhD medical statistician, but no safeguards against bias were explicitly described.
Key takeaways
- 01
After 12 months, bones lost 2.6% to 4.4% of density in the spine and 2.1% to 3.8% in the hip — no matter which treatment they got.
- 02
The chance of breaking a hip in 10 years stayed under 3%, and breaking any major bone stayed under 6%.
- 03
Even though bones got weaker, the risk of breaking a bone didn’t go up enough to be a big concern in this group — it stayed low.
Surprising findings
- CAB (the more aggressive combo therapy) didn’t cause more bone loss than GnRH monotherapy.Prior studies suggested CAB might be worse for bones because it blocks more hormones—but this study found no difference, contradicting assumptions about treatment intensity.
- The 10-year fracture risk remained below 3% for hip fractures despite measurable bone loss.Doctors often assume any bone density drop = high fracture risk, but here, even with 4.4% spine loss, fracture probability stayed low—suggesting FRAX® may be underestimating resilience in this population.
Practical takeaways
If you're on prostate cancer hormone therapy, ask your doctor for a DEXA scan and FRAX® calculation—but don’t panic if bone density drops slightly.
This study only looked at 12 months; long-term effects beyond a year are unknown, and the sample was small and non-randomized.
medium confidenceFocus on weight-bearing exercise—70% of participants in this study exercised, and it may help offset bone loss even if it wasn’t statistically significant.
Exercise data was self-reported and imbalanced between groups—CAB patients exercised less at baseline, so it’s unclear how much it helped.
low confidenceWhy this study matters
Both treatments hurt bones equally
Over 12 months, men on combined androgen block (CAB) lost 2.6% of bone density in the spine, while those on GnRH agonist monotherapy lost 4.4%—but the difference wasn't statistically significant. Hip bone loss was 2.1–3.8% in both groups.
Most people assume stronger treatments cause more side effects, but here, the more aggressive combo therapy (CAB) didn’t harm bones more than the simpler one—challenging assumptions about treatment intensity.
Fracture risk stayed under 3%
Despite measurable bone loss, the 10-year probability of hip fracture remained below 3% and major osteoporotic fracture below 6% in both groups—well below the 3% and 20% clinical thresholds for drug intervention.
Even though bones weakened, the actual risk of breaking a bone didn’t spike—meaning bone density alone doesn’t tell the whole story about fracture risk.
Age was the only real predictor
The study found age was the only factor significantly linked to bone loss—but the clinical impact was 'negligible.' Even older men didn’t lose bone dramatically faster than younger ones.
It’s counterintuitive: you’d expect older men to lose bone faster, but the data says the hormone therapy itself is the main driver—not age or lifestyle.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Men with prostate cancer get a treatment that lowers testosterone to fight cancer, but this can make bones weaker. This study checked if two types of this treatment hurt bones differently.
Research results
After 12 months, bones lost 2.6% to 4.4% of density in the spine and 2.1% to 3.8% in the hip — no matter which treatment they got. The chance of breaking a hip in 10 years stayed under 3%, and breaking any major bone stayed under 6%.
What this means - more context
Even though bones got weaker, the risk of breaking a bone didn’t go up enough to be a big concern in this group — it stayed low.
To compare bone mineral density (BMD) loss between combined androgen block (CAB) and GnRH agonist monotherapy in Asian prostate cancer patients over 12 months of androgen deprivation therapy (ADT), and assess fracture risk.
Over 12 months of ADT, both CAB and GnRH agonist monotherapy caused significant BMD loss at the lumbar spine (mean: -2.6% and -4.4%) and femoral regions, with no statistically significant difference between treatments. The proportion of osteopenia/osteoporosis increased slightly but not significantly. The 10-year probability of hip fracture remained below 3% and major osteoporotic fracture below 6% in both groups. Age was the only significant factor linked to BMD loss, but its clinical impact was negligible.
Methods Used
Multi-center, prospective, observational cohort study of 253 Asian prostate cancer patients (196 CAB, 57 GnRH) receiving ADT. BMD measured via DEXA at baseline and 12 months; fracture risk estimated using FRAX®. Statistical analysis included paired and two-sample t-tests, multiple regression.
Main Finding
BMD significantly decreased at the lumbar spine (mean -2.6% with CAB, -4.4% with GnRH) and femoral regions after 12 months of ADT, with no significant difference between treatments. The 10-year probability of hip fracture remained below 3% and major osteoporotic fracture below 6% in both groups, indicating no clinically significant increase in fracture risk.
Confidence Level
Moderate. Prospective design and use of DEXA/FRAX® strengthen validity, but small sample size (especially GnRH group), non-randomization, lack of testosterone measurements, and use of Japanese FRAX® instead of validated Korean model limit reliability.
Study Flags
Red Flags
- •Non-randomized and imbalanced group sizes (CAB: 196, GnRH: 57)
- •Use of Japanese FRAX® model instead of validated Korean version for fracture risk estimation
- •No serum testosterone levels measured to confirm hormonal suppression
Surprising Findings
CAB (the more aggressive combo therapy) didn’t cause more bone loss than GnRH monotherapy.
Prior studies suggested CAB might be worse for bones because it blocks more hormones—but this study found no difference, contradicting assumptions about treatment intensity.
Practical Takeaways
If you're on prostate cancer hormone therapy, ask your doctor for a DEXA scan and FRAX® calculation—but don’t panic if bone density drops slightly.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 556 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Human Cohort Study
Subject
Moderate probability
on the GRADE evidence scale
This study watched two groups of men with prostate cancer over a year to see how their bones changed after different treatments. It found that both treatments made bones weaker, but it couldn't say for sure if one was worse than the other because the doctors chose which treatment each man got — not by chance.
No conflicts of interest were detected in this study. No score impact.
Strengths
- Prospective design with longitudinal BMD measurements over 12 months
- Multi-center recruitment across 10 major hospitals in South Korea
- Use of standardized DEXA scans and FRAX® for fracture risk estimation
Weaknesses
- No randomization — treatment assignment was non-random and based on physician preference
- Blinding was unknown and likely absent, introducing detection and reporting bias
- Severe imbalance in group sizes (CAB: n=196 vs. GnRH: n=57)
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Men with prostate cancer get a treatment that lowers testosterone to fight cancer, but this can make bones weaker. This study checked if two types of this treatment hurt bones differently.
Research results
After 12 months, bones lost 2.6% to 4.4% of density in the spine and 2.1% to 3.8% in the hip — no matter which treatment they got. The chance of breaking a hip in 10 years stayed under 3%, and breaking any major bone stayed under 6%.
What this means - more context
Even though bones got weaker, the risk of breaking a bone didn’t go up enough to be a big concern in this group — it stayed low.
To compare bone mineral density (BMD) loss between combined androgen block (CAB) and GnRH agonist monotherapy in Asian prostate cancer patients over 12 months of androgen deprivation therapy (ADT), and assess fracture risk.
Over 12 months of ADT, both CAB and GnRH agonist monotherapy caused significant BMD loss at the lumbar spine (mean: -2.6% and -4.4%) and femoral regions, with no statistically significant difference between treatments. The proportion of osteopenia/osteoporosis increased slightly but not significantly. The 10-year probability of hip fracture remained below 3% and major osteoporotic fracture below 6% in both groups. Age was the only significant factor linked to BMD loss, but its clinical impact was negligible.
Methods Used
Multi-center, prospective, observational cohort study of 253 Asian prostate cancer patients (196 CAB, 57 GnRH) receiving ADT. BMD measured via DEXA at baseline and 12 months; fracture risk estimated using FRAX®. Statistical analysis included paired and two-sample t-tests, multiple regression.
Main Finding
BMD significantly decreased at the lumbar spine (mean -2.6% with CAB, -4.4% with GnRH) and femoral regions after 12 months of ADT, with no significant difference between treatments. The 10-year probability of hip fracture remained below 3% and major osteoporotic fracture below 6% in both groups, indicating no clinically significant increase in fracture risk.
Confidence Level
Moderate. Prospective design and use of DEXA/FRAX® strengthen validity, but small sample size (especially GnRH group), non-randomization, lack of testosterone measurements, and use of Japanese FRAX® instead of validated Korean model limit reliability.
Study Flags
Red Flags
- •Non-randomized and imbalanced group sizes (CAB: 196, GnRH: 57)
- •Use of Japanese FRAX® model instead of validated Korean version for fracture risk estimation
- •No serum testosterone levels measured to confirm hormonal suppression
Surprising Findings
CAB (the more aggressive combo therapy) didn’t cause more bone loss than GnRH monotherapy.
Prior studies suggested CAB might be worse for bones because it blocks more hormones—but this study found no difference, contradicting assumptions about treatment intensity.
Practical Takeaways
If you're on prostate cancer hormone therapy, ask your doctor for a DEXA scan and FRAX® calculation—but don’t panic if bone density drops slightly.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 556 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Human Cohort Study
Subject
Moderate probability
on the GRADE evidence scale
This study watched two groups of men with prostate cancer over a year to see how their bones changed after different treatments. It found that both treatments made bones weaker, but it couldn't say for sure if one was worse than the other because the doctors chose which treatment each man got — not by chance.
No conflicts of interest were detected in this study. No score impact.
Strengths
- Prospective design with longitudinal BMD measurements over 12 months
- Multi-center recruitment across 10 major hospitals in South Korea
- Use of standardized DEXA scans and FRAX® for fracture risk estimation
Weaknesses
- No randomization — treatment assignment was non-random and based on physician preference
- Blinding was unknown and likely absent, introducing detection and reporting bias
- Severe imbalance in group sizes (CAB: n=196 vs. GnRH: n=57)
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
The study tried hard by measuring bones carefully and tracking many things like age and exercise, but it wasn't fair because the doctors picked who got which treatment, and one group had way more men than the other. That makes it harder to trust the results — it's like comparing a big class to a tiny one and saying they're the same, even though they started out different.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
49 / 100
- Randomizationnot randomized
- Blindingblinding unclear
- Control group+15/15
- Sample size (n=253)+14.4/20
- Follow-up+10/10
100 / 100
77 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 556 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. This is an observational cohort study without randomization or blinding, so it cannot rule out confounding factors (e.g., baseline differences in prostate volume, nodal stage, exercise levels, and treatment selection bias). The assignment to treatment groups was based on physician discretion, not random assignment, making it impossible to conclude that one treatment caused different bone loss outcomes.
No Conflicts
No conflicts of interest identified
No conflicts of interest or funding disclosures were reported in the study text. The study appears to be independently conducted without industry involvement.
The study was conducted across 10 university hospitals in South Korea with institutional review board approvals and informed consent. No industry sponsors, author affiliations with pharmaceutical companies, or funding disclosures were identified. The statistical analysis was performed by a PhD medical statistician, but no safeguards against bias were explicitly described.
Standing
Who’s using this study?
The videos and claims on this site that lean on this study, and the researchers who wrote it.
1 video from Dr Brad Stanfield cite this study, drawing 1 claim from it.
- Very strong evidence
Randomized or controlled trials support this claim, alongside consistent supporting evidence.
Evidence
Authored by
15 researchersIf this is your work, this is how we attribute it on Fit Body Science. Jae Young Joung is listed as the lead author.